Product Pipeline
A number of targeted anticancer compounds are now in clinical testing through our own product programs and those of our partners. Information on the relevant subtypes of each cancer can be found in the discussion of each comound.
| Program | Indication | Pre-Clinical | Phase I | Phase II | Phase III | |
|---|---|---|---|---|---|---|
Lorvotuzumab mertansine |
Small-cell lung cancer |
 |
|
|
||
Multiple myeloma |
|
|
||||
IMGN529 |
NHL |
|
|
|||
IMGN853 |
Solid tumors |
|
|
* |
||
Trastuzumab emtansine for HER2+ Breast Cancer |
Metastatic – after Herceptin, taxane |  |
|
|
|
|
Metastatic – 1st line |
|
|
|
|
|
|
| Metastatic – after Herceptin, Tykerb | |
|
|
|
||
(Neo)adjuvant |
|
|
|
|||
Other (non-breast) cancer |
|
|||||
SAR3419 |
DLBCL – single agent |
 |
|
|
||
DLBCL – in combination |
|
|
|
|||
B-ALL |
|
|
|
|||
SAR650984** |
Blood cancers |
|
|
|||
SAR566658 |
Solid tumors |
|
|
|||
BT-062 |
Multiple myeloma |
 |
|
|||
BAY 94-9343 |
Solid tumors |
 |
|
|||
Amgen 1 |
Undisclosed |
 |
|
|||
Amgen 2 |
Undisclosed |
|
|
|
ImmunoGen | |
Roche |
|
Sanofi | |
Biotest |
|
Bayer | |
Amgen |
* IND now active
** Naked antibody
NHL: Non-Hodgkin's lymphoma
DLBCL: Diffuse large B-cell lymphoma
B-ALL: B-cell acute lymphoblastic leukemia
Last updated April 17, 2012
